Patents by Inventor Nancy E. Lane

Nancy E. Lane has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treating inflammation using LLP2A-bisphosphonate conjugates and mesenchymal stem cells
    Patent number: 12594340
    Abstract: The present invention provides methods of treating a subject having a primary inflammatory disease or disorder comprising administering to the subject a composition comprising a conjugate of an LLP2A peptidomimetic ligand and a bisphosphonate drug, wherein the composition comprising the LLP2A-bisphosphonate conjugate enhances the delivery of mesenchymal stem cells to a site of inflammation. Methods of enhancing an anti-inflammatory or immunomodulatory property of mesenchymal stem cells, comprising administering to a subject in need thereof the mesenchymal stem cells and a composition comprising a conjugate of an LLP2A peptidomimetic ligand and a bisphosphonate drug, are also provided.
    Type: Grant
    Filed: January 5, 2021
    Date of Patent: April 7, 2026
    Assignee: The Regents of the University of California
    Inventors: Nancy E. Lane, Ruiwu Liu, Wei Yao, Kit S. Lam
  • TREATING INFLAMMATION USING LLP2A-BISPHOSPHONATE CONJUGATES AND MESENCHYMAL STEM CELLS
    Publication number: 20210401993
    Abstract: The present invention provides methods of treating a subject having a primary inflammatory disease or disorder comprising administering to the subject a composition comprising a conjugate of an LLP2A peptidomimetic ligand and a bisphosphonate drug, wherein the composition comprising the LLP2A-bisphosphonate conjugate enhances the delivery of mesenchymal stem cells to a site of inflammation. Methods of enhancing an anti-inflammatory or immunomodulatory property of mesenchymal stem cells, comprising administering to a subject in need thereof the mesenchymal stem cells and a composition comprising a conjugate of an LLP2A peptidomimetic ligand and a bisphosphonate drug, are also provided.
    Type: Application
    Filed: January 5, 2021
    Publication date: December 30, 2021
    Applicant: The Regents of the University of California
    Inventors: Nancy E. Lane, Ruiwu Liu, Wei Yao, Kit S. Lam
  • TREATING INFLAMMATION USING LLP2A-BISPHOSPHONATE CONJUGATES AND MESENCHYMAL STEM CELLS
    Publication number: 20160243250
    Abstract: The present invention provides methods of treating a subject having a primary inflammatory disease or disorder comprising administering to the subject a composition comprising a conjugate of an LLP2A peptidomimetic ligand and a bisphosphonate drug, wherein the composition comprising the LLP2A-bisphosphonate conjugate enhances the delivery of mesenchymal stem cells to a site of inflammation. Methods of enhancing an anti-inflammatory or immunomodulatory property of mesenchymal stem cells, comprising administering to a subject in need thereof the mesenchymal stem cells and a composition comprising a conjugate of an LLP2A peptidomimetic ligand and a bisphosphonate drug, are also provided.
    Type: Application
    Filed: October 3, 2014
    Publication date: August 25, 2016
    Inventors: Nancy E. Lane, Ruiwu Liu, Wei Yao, Kit S. Lam